Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma

Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma Publisher

Samimi H¹ ; Haghpanah V^{1, 2}

Show Affiliations

1. Endocrinology and Metabolism Research Center (EMRC), Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2. Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Cancer Cell International Published:2022

Abstract

Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated with DTC during progression towards RAI-R DTC, including thyroid-stimulating hormone levels, may help to explain the pathophysiology of challenging RAI-R DTC clinical cases. Graphical Abstract: [Figure not available: see fulltext.] © 2022, The Author(s).

Related Docs

1. Gut Microbiome and Radioiodine-Refractory Papillary Thyroid Carcinoma Pathophysiology, Trends in Endocrinology and Metabolism (2020)

2. Thyroid Cancer Research at Endocrinology and Metabolism Research Institute (Emri): A Report of Scientific Activities Between 2005 and 2020, Journal of Diabetes and Metabolic Disorders (2021)

Experts (# of related papers)

View all Related Experts

Vahid Haghpanah (2)

Mohammad Reza Mohajeri Tehrani (1)

Style	Citing Format
MLA	Samimi H, Haghpanah V. "Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma." Cancer Cell International, vol. 22, no. 1, 2022, pp. -.
APA	Samimi H, Haghpanah V (2022). Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma. Cancer Cell International, 22(1), -.
Chicago	Samimi H, Haghpanah V. "Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma." Cancer Cell International 22, no. 1 (2022): -.
Harvard	Samimi H, Haghpanah V (2022) 'Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma', Cancer Cell International, 22(1), pp. -.
Vancouver	Samimi H, Haghpanah V. Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma. Cancer Cell International. 2022;22(1):-.
BibTex	@article{ author = {Samimi H and Haghpanah V}, title = {Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma}, journal = {Cancer Cell International}, volume = {22}, number = {1}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Samimi H AU - Haghpanah V TI - Molecular Evidence Reveals Thyrotropin Intervention Enhances the Risk of Developing Radioiodine-Refractory Differentiated Thyroid Carcinoma JO - Cancer Cell International VL - 22 IS - 1 SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract